Prohost Biotech
HomeArticlesImpacting NewsBridgeBio Pharma product BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Impacting News
Premium

BridgeBio Pharma product BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio Pharma in the NEWS On March 11, 2026, BridgeBio Pharma ( BBIO ) presented additional positive data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in indivi...
P

Prohost Biotech

1 min read
46
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

BridgeBio Pharma (BBIO)

Comments (0)

Please sign in to join the discussion

Related Articles

Impacting News
Premium

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of   $191.2 million, representing 57% year-over-year growth   AUVELITY ®   1Q 2026 net product sales of   $153.2 million, representing 59% year-over-year growth   SUN...
P

Prohost Biotech

May 6, 2026

1m
254
Impacting News
Premium

Neurocrine Biosciences Acquires Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Neurocrine ...
P

Prohost Biotech

Apr 8, 2026

1m
196
Impacting News
Premium

FDA Approved Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions

Eli Lilly in the NEWS INDIANAPOLIS, April 1, 2026 /PRNewswire/, Eli Lilly and Company ( LLY ) , announced the U.S. FDA approved Foundayo™ (orforglipron) for adults with obesity, or overweight with wei...
P

Prohost Biotech

Apr 2, 2026

1m
232